The Philadelphia Inquirer / HealthDay News, February 27, 2014

Dozens of experts and health care agencies sent a letter this week urging that the U.S. Food and Drug Administration revoke its approval of the supercharged painkiller, Zohydro. In the petition sent to the FDA on Wednesday, more than 40 consumer watchdog groups, addiction treatment groups and others noted that the drug was approved despite significant resistance from the FDA's own advisory committee, which voted 11-2 against allowing Zohydro to be sold. According to consumer advocate group Public Citizen, which issued its own news release on the issue Wednesday, a single dose of Zohydro could kill a child.
Facebook icon
LinkedIn icon
Twitter icon